Thermo Fisher Scientific on the value of an integrated approach to drug development
For pharma and biotech companies today, traditional reliance on multiple vendors to manage different aspects of drug development may compound challenging market dynamics, such as escalating development costs, increasing scientific and logistical demands, regulatory complexity, and more.
To address this, Thermo Fisher Scientific now offers Accelerator Drug Development: a suite of integrated services combining CDMO and CRO capabilities to streamline the drug development journey, from early-stage research to commercialisation.
In a new sponsored video, pharmaphorum web editor Nicole Raleigh spoke with Thermo Fisher Scientific’s Alberto Fernández, Head of Clinical Development Strategy & Innovation, who discussed the company’s purposes behind the solution and how its different approach can help support small and mid-size biotech, as well as large pharma, across all major drug modalities and therapeutic areas.
Watch the video today and find out more about how Thermo Fisher Scientific’s Accelerator Drug Development solution can help address your organisation’s unique needs.
About the interviewee
Alberto Fernández is a distinguished global life-sciences and pharma R&D executive, currently serving as the Head of Clinical Development Strategy and Innovation at Thermo Fisher Scientific. In this role, he partners across digital and corporate functions to drive forward-thinking strategies and innovations in clinical research. With a career spanning over 32 years, Alberto has a proven track record of leading end-to-end clinical development. He is recognised for his ability to accelerate portfolio delivery, modernise operations, and scale digital and AI initiatives within large, complex organisations. His journey in the industry began as a Clinical Research Associate (CRA) in Spain, and he has since advanced through roles of increasing responsibility, including executive leadership positions as head of global clinical and development operations both at GSK and AstraZeneca.
Alberto He holds a Bachelor of Science (BSc) and a Master of Science (MSc) in Biology from the Universidad Complutense de Madrid. Additionally, he earned a Global Executive MBA from IESE Business School and further honed his leadership skills through the International Advanced Management Program at IESE and executive leadership programs at Harvard Business School.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
